Bayern; Oberbayern; Bad Tölz-Wolfratshausen
Location of affected unit(s)
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations

300 jobs
Number of planned job losses
Job loss
Announcement Date
10 April 2023
Employment effect (start)
10 March 2023
Foreseen end date
31 December 2023


Haupt Pharma, a developer and manufacturer of pharmaceutical products and food supplements and a subsidiary of the Aenova Group, announced 300 jobs cuts. The closure of the Wolfrathshausen site was announced by the company on 1 March 2023 and will be implemented by the end of 2023.

The reason for the closure is a restructuring programme, as a result of which the Wolfratshausen site will be closed, as a comprehensive renovation would be necessary to comply with additional official requirements, which, according to the company, would not be economically viable. All 300 jobs at the site are affected by the closure. According to the company, negotiations with the works council on a social plan have already begun.

The Aenova Group is headquartered near Munich and has 15 production sites, several sales offices and more than 4,300 employees worldwide in Europe, the USA, Asia and Australia.



Eurofound (2023), Haupt Pharma, Closure in Germany, factsheet number 108751, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/108751.